Abstract
Oral delivery of therapeutics is the preferred route of administration due to ease of administration which is associated with greater patient medication adherence. One major barrier to oral delivery and intestinal absorption is rapid clearance of the drug and the drug delivery system from the gastrointestinal (GI) tract. To address this issue, researchers have investigated using GI mucus to help maximize the pharmacokinetics of the therapeutic; while mucus can act as a barrier to effective oral delivery, it can also be used as an anchoring mechanism to improve intestinal residence. Nano-drug delivery systems that use materials which can interact with the mucus layers in the GI tract can enable longer residence time, improving the efficacy of oral drug delivery. This review examines the properties and function of mucus in the GI tract, as well as diseases that alter mucus. Three broad classes of mucus-interacting systems are discussed: mucoadhesive, mucus-penetrating, and mucolytic drug delivery systems. For each class of system, the basis for mucus interaction is presented, and examples of materials that inform the development of these systems are discussed and reviewed. Finally, a list of FDA-approved mucoadhesive, mucus-penetrating, and mucolytic drug delivery systems is reviewed. In summary, this review highlights the progress made in developing mucus-interacting systems, both at a research-scale and commercial-scale level, and describes the theoretical basis for each type of system.
Introduction: The GI Mucus Barrier
Oral drug delivery remains the gold standard for patient compliance, yet it faces significant physiological hurdles, including extreme pH variations, digestive enzymes, and rapid transit through the gastrointestinal (GI) tract. A critical barrier to effective absorption is the mucus layer—a complex, viscoelastic gel primarily composed of mucin proteins. While designed to trap and clear pathogens, this layer also traps drug delivery systems, leading to their rapid elimination through natural mucus turnover.
Researchers at MIT and Harvard have reviewed how this perceived barrier can be re-engineered into a target to enhance drug residence time and bioavailability. By understanding the regional distribution and biochemical properties of mucins, scientists can design nanoparticles that either adhere to or penetrate this protective layer.
Engineering Paradigms for Mucus Interaction
The review categorizes nano-delivery systems into three primary engineering strategies:
1. Mucoadhesive Systems
These systems utilize polymers such as chitosan, carbomers, or alginate to form physical or chemical bonds with mucins. A notable technique is thiolation—the addition of sulfur groups—which enables nanoparticles to form covalent disulfide bonds with mucus, effectively "anchoring" the delivery system within the GI tract. Thiolated carbomers have demonstrated a 9.2-fold improvement in mucus retention after three hours compared to unmodified versions.
2. Passive Mucus-Penetrating Systems
In contrast to adhesive strategies, these systems are designed to be "slippery." By coating nanoparticles with high densities of low-molecular-weight polyethylene glycol (PEG) or poloxamers, a neutral surface is created. This prevents the electrostatic and hydrophobic interactions that typically trap particles in the mucus mesh. PEGylated nanoparticles have achieved diffusion coefficients 380 to 1100 times higher than uncoated particles in human mucus.
3. Active Mucolytic Systems
These systems take an aggressive approach by incorporating mucolytic agents (e.g., N-acetylcysteine) or enzymes (e.g., papain or bromelain). These agents locally degrade the mucus gel's crosslinks, creating a path for the drug to penetrate the barrier. To maintain safety, recent research focuses on immobilizing these enzymes on the nanoparticle surface to limit action to the particle's immediate path.
Key Insights: Navigating Biological Variability
A central challenge in designing these systems is the inherent heterogeneity of the GI tract. As shown in the regional mapping of mucins, different sections of the gut express distinct mucin types—such as MUC5B in the esophagus, MUC5AC and MUC6 in the stomach, and MUC2 in the intestines.
- The Turnover Paradox: While mucoadhesion increases residence time, it is limited by the rapid turnover of the outer mucus layer (hours). To achieve multi-day delivery, systems must penetrate to the more stable epithelial surface, which turns over every 3–5 days.
- PEG Density: The review emphasizes that the surface density of PEG is more critical than its molecular weight for achieving effective mucus penetration; only a dense coating can shield the nanoparticle core from sticky mucin domains.
- Disease-Specific Targeting: Alterations in mucin expression and glycosylation during diseases like ulcerative colitis or colorectal cancer provide unique "zip codes" for targeted drug delivery.
Clinical Impact and Future Directions
The transition from laboratory research to clinical application is already underway, with over 20 FDA-approved formulations leveraging these principles. For instance, chitosan-coated nanoparticles have shown a 16-fold increase in insulin bioavailability compared to oral solutions.
However, several challenges remain. Future research must address "back-diffusion" (particles diffusing back into the lumen), the impact of the "protein corona" (proteins and lipids coating the particle in the gut), and the significant biological variability across different patient populations. By refining these mucus-interacting strategies, the next generation of oral nano-medicines can overcome the GI barrier to provide more effective and reliable therapies.
Summary updated